Farallon's new passive stake signals conviction in Exelixis following strong Q3 results and maintained guidance. Monitor for any future 13D conversion or additional accumulation, though the filing explicitly disclaims activist intent.
EXEL drugs
EXEL drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $70.58entry
- T+1 · 6d ago +0.17%α −1.15% · $70.70
- T+4 · todayOpen
- T+5 · in 7h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Farallon Capital Management disclosed a new 5%+ passive stake in Exelixis, reporting beneficial ownership of 14,694,910 shares (approximately 4.7% of shares outstanding based on the $16.8B market cap and snapshot price). The filing certifies passive intent under Rule 13d-1(b) and follows Exelixis's Q3 2026 earnings beat and maintained guidance.
Key Financial Metrics
Key Facts
- Farallon Capital Management filed a new Schedule 13G disclosing beneficial ownership of 14,694,910 shares of Exelixis common stock
- The filing certifies passive intent under Rule 13d-1(b), with no purpose or effect of changing or influencing control
- Shares are held through eight Farallon investment partnerships including Farallon Capital Partners, L.P. and Farallon Capital Institutional Partners, L.P.
- Farallon is a hedge fund manager; this is a new 13G filing (not an amendment) for Exelixis
- Exelixis reported Q3 2026 revenue of $658.7M (up 10.2% YoY) and GAAP diluted EPS of $0.85 (up 23.2% YoY) on October 29, 2026
Financial Impact
14,694,910 shares disclosed; approximately 4.7% of shares outstanding based on $16.8B market cap and snapshot price
Risk Factors
- No specific risks identified from this passive 13G filing
- Farallon could increase or decrease position without additional disclosure until crossing 5% thresholds
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000908834-26-000516 |
| Document: 0000908834-26-000516-index-headers.html | 0000908834-26-000516 |
| Document: 0000908834-26-000516-index.html | 0000908834-26-000516 |
| Document: 0000908834-26-000516.txt | 0000908834-26-000516 |
Track record
16 reports on EXEL
0 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +21.97% at T+60 after the Feb 28, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago SC 13G Neutral 3/10 Viewing Entry $70.58 to $70.70 Now $67.10 −4.93% ▲ +0.17% −1.15% vs SPY
- Nov 9, 20267d ago SC 13D/A Bearish 5/10 Entry $70.58 to $70.70 Now $67.10 +4.93% ▼ −0.17% +1.15% vs SPY
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $69.39 to $70.13 Now $67.10 −3.30% ▲ +1.07% +1.55% vs SPY
- Oct 20, 202627d ago Institutional Cluster Neutral 2/10 Entry $64.58 to $65.31 Now $67.10 +3.90% ▲ +1.13% +2.31% vs SPY
- Oct 12, 20265w ago Institutional Cluster Neutral 3/10 Entry $59.82 to $59.51 Now $67.10 +12.17% ▼ −0.52% −0.51% vs SPY
- Sep 11, 20269w ago 8-K Bearish 6/10 Entry $56.12 to $56.21 Now $67.10 −19.57% ▼ −0.16% −0.61% vs SPY
- Jun 3, 202623w ago Insider Cluster Neutral 2/10 Entry $52.39 to $52.69 Now $67.10 +28.08% ▲ +0.57% +3.17% vs SPY
- May 29, 202624w ago 8-K Neutral 3/10 Entry $50.20 to $48.49 Now $67.10 +33.67% ▼ −3.41% −3.55% vs SPY
- May 28, 202624w ago Insider Cluster Neutral 3/10 Entry $50.32 to $50.28 Now $67.10 +33.35% ▼ −0.08% −0.35% vs SPY
- May 28, 202624w ago Insider Cluster Neutral 3/10 Entry $50.32 to $50.28 Now $67.10 +33.35% ▼ −0.08% −0.35% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers